- Home
- SAVA vs BYSI Comparison
SAVA vs BYSI Comparison
Compare SAVA & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- BYSI
- Stock Information
- Founded
- SAVA 1998
- BYSI 2010
- Country
- SAVA United States
- BYSI United States
- Employees
- SAVA 30
- BYSI N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- BYSI Health Care
- Exchange
- SAVA Nasdaq
- BYSI Nasdaq
- Market Cap
- SAVA 70.5M
- BYSI 72.1M
- IPO Year
- SAVA N/A
- BYSI 2017
- Fundamental
- Price
- SAVA $1.57
- BYSI $1.60
- Analyst Decision
- SAVA Buy
- BYSI
- Analyst Count
- SAVA 3
- BYSI 0
- Target Price
- SAVA $54.50
- BYSI N/A
- AVG Volume (30 Days)
- SAVA 1.2M
- BYSI 24.2K
- Earning Date
- SAVA 05-09-2025
- BYSI 01-01-0001
- Dividend Yield
- SAVA N/A
- BYSI N/A
- EPS Growth
- SAVA N/A
- BYSI N/A
- EPS
- SAVA N/A
- BYSI N/A
- Revenue
- SAVA N/A
- BYSI N/A
- Revenue This Year
- SAVA N/A
- BYSI N/A
- Revenue Next Year
- SAVA N/A
- BYSI N/A
- P/E Ratio
- SAVA N/A
- BYSI N/A
- Revenue Growth
- SAVA N/A
- BYSI N/A
- 52 Week Low
- SAVA $1.15
- BYSI $0.98
- 52 Week High
- SAVA $42.20
- BYSI $3.63
- Technical
- Relative Strength Index (RSI)
- SAVA 45.15
- BYSI 60.39
- Support Level
- SAVA $1.37
- BYSI $1.31
- Resistance Level
- SAVA $1.73
- BYSI $1.67
- Average True Range (ATR)
- SAVA 0.13
- BYSI 0.13
- MACD
- SAVA 0.08
- BYSI 0.06
- Stochastic Oscillator
- SAVA 76.72
- BYSI 89.34
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.